Pure Antiestrogens and Breast Cancer

References

• DeFriend DJ, Howell A, Nicholson RI et al. Investigation of a new pure antiestrogen (ICI 182 780) in women with primary breast cancer. Cancer Res 1994;54:408–14
   PubMed Web of Science ®Google Scholar
• Osborne CK, Coronado EB, Robinson JP. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol 1987;23:1189–96
   PubMedGoogle Scholar
• Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995;87:746–50
   PubMed Web of Science ®Google Scholar
• Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res 1995;1:467–72
   PubMed Web of Science ®Google Scholar
• Marrow M, Jordan VC. Molecular mechanism of resistance to tamoxifen therapy in breast cancer. Arch Surg 1993;128:1187–91
   PubMed Web of Science ®Google Scholar
• Hyder SM, Stancel GM, Chiapetta C et al. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res 1996;56:3954–60
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Dukes M, Bowler J. A potent specific antiestrogen with clinical potential. Cancer Res 1991;51:3867–73
   PubMed Web of Science ®Google Scholar
• Lyman SD, Jordan VC. Possible mechanisms for the agonist actions of tamoxifen and the antagonist actions of MER-25 (ethamoxytriphetol) in the mouse uterus. Biochem Pharmacol 1985;34:2795–806
   PubMed Web of Science ®Google Scholar
• Fornander T, Rutqvist LE, Cedermark B et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1989;1:117–20
   PubMed Web of Science ®Google Scholar
• Jordan VC, Haldemann B, Allen KE. Geometric isomers of substituted triphenylethylenes and antiestrogen action. Endocrinology 1981;108:1353–61
   Google Scholar
• Gusberg SB. Tamoxifen for breast cancer: associated endometrial cancer. Cancer 1990;65:1463–4
   PubMed Web of Science ®Google Scholar
• Nawata H, Bronzert D, Lippman ME. Isolation and characterization of a tamoxifen-resistant cell line derived from MCF-7 human breast-cancer cells. J Biol Chem 1981;256: 5016–21
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Jiang S-Y, Jeng M-H et al. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res 1989;49:4090–93
   PubMed Web of Science ®Google Scholar
• Hu XF, Veroni M, De Luise M et al. Cicumvention of tamoxifen resistance by the pure antiestrogen ICI 182,780. Int J Cancer 1993;55: 873–6
   PubMed Web of Science ®Google Scholar
• Osborne CK, Coronado E, Allred DC et al. Acquired tamoxifen resistance: correlation with reduced breast-tumour levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen. J Natl Cancer Inst 1991;83:1477–82
   PubMed Web of Science ®Google Scholar
• Pavlik EJ, Nelson K, Srinivasan S. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity. Cancer Res 1992;52:4106–12
   PubMed Web of Science ®Google Scholar
• Levenson AS, Catherino WH, Jordan VC. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol 1997;60:261–8
   PubMed Web of Science ®Google Scholar
• Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumours in athymic mice after long-term antiestrogen administration. Cancer Res 1988;48:5183–7
   PubMed Web of Science ®Google Scholar
• Turken S, Siris E, Seldon D et al. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989;81:1086–8
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Jordan VC. Clinical potential of new antiestrogens. J Clin Oncol 1997;15:840–52
   PubMed Web of Science ®Google Scholar
• Dukes M, Miller D, Wakeling AE et al. Antiuterotropic effects of a pure antiestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys. J Endocrinol 1992;135:239–47
   PubMed Web of Science ®Google Scholar
• Thompson EW, Katz D, Shima TB et al. ICI 164 384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res 1989;49:6929–34
   PubMed Web of Science ®Google Scholar
• Dukes M, Waterton JC, Wakeling AE. Antiuterotropic effects of the pure antiestrogen ICI 182 780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging. J Endocrinol 1993;138: 203–9
   PubMed Web of Science ®Google Scholar
• Howell A, DeFriend DJ, Robertson JFR et al. Pharmacokinetics, pharmacological and antitumour effects of the specific antiestrogen ICI 182 780 in women with advanced breast cancer. Br J Cancer 1996;74:300–08
   PubMed Web of Science ®Google Scholar
• Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988;240:889–95
   PubMed Web of Science ®Google Scholar
• Carson-Jurice MA, Schrader WT, O’Malley BW. Steroid receptor superfamily: structure and functions. Endocr Rev 1990;11:201–20
   PubMed Web of Science ®Google Scholar
• Ham J, Parker MG. Regulation of expression by nuclear hormone receptors. Curr Opin Cell Biol 1989;1:503–11
   PubMed Web of Science ®Google Scholar
• Beato M. Gene regulation by steroid hormones. Cell 1989;56:335–44
   PubMed Web of Science ®Google Scholar
• Gibson MK, Nemmers LA, Beckman WC et al. The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 1991;129:2000–10
   PubMed Web of Science ®Google Scholar
• Dauvois S, White R, Parker MG et al The antiestrogen ICI 182 780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993;106:1377–88
   PubMed Web of Science ®Google Scholar
• Fawell SE, White R, Hoare S et al. Inhibition of estrogen receptor-DNA binding by the ‘pure’ antiestrogen ICI 164 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990;87:6883–7
   PubMed Web of Science ®Google Scholar
• Howell A, Osborne CK, Morris C et al. ICI 182,780 (Faslodex). Development of a novel ‘pure’ antiestrogen. Cancer 2000;89:817–24
   Google Scholar
• Dauvois S, Danielian PS, White R et al. Antiestrogen ICI 164 384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992;89:4037–41
   PubMed Web of Science ®Google Scholar
• Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 1996;56:2321–30
   PubMed Web of Science ®Google Scholar
• Wakeling AE. Similarities and distinctions in the mode of action of different classes of antiestrogens. Endocr Rel Cancer 2000;7:17–28
   PubMed Web of Science ®Google Scholar
• Coopman P, Garcia M, Brunner N et al. Antiproliferative and antiestrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast cancer cells. Int J Cancer 1994;56:295–300
   PubMed Web of Science ®Google Scholar
• Cavailles V, Augereau P, Garcia M et al. Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells. Nucleic Acid Res 1988;16:1903–19
   PubMed Web of Science ®Google Scholar
• Nawaz Z, Stancel GM, Hyder SM. The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription. Cancer Res 1999;59: 372–6
   PubMed Web of Science ®Google Scholar
• Huynth HT, Pollak M. Insulin-like growth factor I gene expression in uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182 780. Cancer Res 1993;53:5585–8
   PubMed Web of Science ®Google Scholar
• Murphy L, Ghahary A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev 1990;11:443–53
   PubMed Web of Science ®Google Scholar
• Steller MA, Delgado CH, Bartels CJ et al. Overexpression of the insulin-like growth factor-I receptor and autocrine stimulation in human cervical cancer cells. Cancer Res 1996;56:1761–5
   PubMed Web of Science ®Google Scholar
• Huynth H, Nickerson T, Pollak M et al. Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182 780. Clin Cancer Res 1996;2:2037–42
   PubMed Web of Science ®Google Scholar
• Lykkesfeldt AE, Larsen SS, Briand P. Human breast cancer cell lines resistant to pure antiestrogens are sensitive to tamoxifen treatment. Int J Cancer 1995;56:529–34
   Google Scholar
• Labrie F, Labrie C, Belanger A et al. EM-652 (SCH 57068), a third generation SERM acting as a pure antiestrogen in the mammary gland and endometrium. J Steroid Biochem Mol Biol 1999;69:51–84
   PubMed Web of Science ®Google Scholar
• Assikis VJ, Neven P, Jordan VC et al. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 1996;32:1464–76
   Web of Science ®Google Scholar
• Dixon JM, Nicholson RI, Robertson JFR et al. Comparison of the short-term biological effects of fulvestrant (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer. Eur J Cancer 2000;36:S73
   PubMedGoogle Scholar
• Thomas EJ, Walton PL, Thomas NM et al. The effects of ICI 182,780, a pure antiestrogen, on the hypothalamic–pituitary–gonadal axis and on endometrial proliferation in premenopausal women. Hum Reprod 1994;9:1991–6
   PubMed Web of Science ®Google Scholar
• Mokbel K. The Twenty-third Annual San Antonio Breast Cancer Symposium. Curr Med Res Opin 2001;16(4):276–84
   PubMedGoogle Scholar
• Tremblay A, Tremblay GB, Labrie C et al. EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta. Endocrinology 1998;139:111–8
   PubMed Web of Science ®Google Scholar
• Schafer JIM, Liu H, Tonetti DA et al. The interaction of raloxifen and the active metabolite of the antiestrogen EM-800 (SC 5705) with human estrogen receptor. Cancer Res 1999;59:4308–13
   PubMed Web of Science ®Google Scholar
• Martel C, Labrie C, Belanger A et al. Comparison of the effects of the new orally active antiestrogen M-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology 1998;139:2486–92
   PubMed Web of Science ®Google Scholar
• Simard J, Labrie C, Belanger A et al. Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47 D, ZR-75–1 and MCF-7 human breast cancer cells in vitro. Int J Cancer 1997;73:104–12
   PubMed Web of Science ®Google Scholar
• Simard J, Sanchez R, Poirier D et al. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifen, droloxifene and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res 1997;57:5494–7
   Google Scholar
• Luo S, Sourla A, Labrie C et al. Effect of twenty four week treatment with the antiestrogen EM-800 on estrogen sensitive parameters in intact and ovariectomized mice. Endocrinology 1998;139:2645–56
   PubMed Web of Science ®Google Scholar
• Martel C, Provencher L, Li X et al. Binding characteristics of novel non-steroidal antiestrogen to the rat uterine estrogen receptors. J Steroid Biochem Mol Biol 1998;64:199–205
   PubMed Web of Science ®Google Scholar
• Couillard S, Labrie C, Gauthier S et al. Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int J Cancer 2000;85:424–9
   PubMed Web of Science ®Google Scholar
• Couillard S, Gutman M, Labrie C et al. Comparison of the effects of the antiestrogens EM-800 and tamoxifen on the growth of human breast ZR-75-1 cancer xenografts in nude mice. Cancer Res 1998;58:60–64
   PubMed Web of Science ®Google Scholar
• Sourla A, Luo S, Labrie C et al. Morphological changes induced by 6-month treatment of intact and ovariectomized mice with tamoxifen and the pure antiestrogen EM-800. Endocrinology 1997;138:5605–17
   PubMed Web of Science ®Google Scholar
• Luo S, Martel C, Suorla A et al. Comparative effects of 28-day treatment with the new antiestrogen EM-800 and tamoxifen on estrogen-sensitive parameters in intact mice. Int J Cancer 1997;73:381–91
   PubMed Web of Science ®Google Scholar
• Luo S, Stojanovic M, Labrie C et al. Inhibitory effect of the novel antiestrogen EM-800 and medroxyprogesterone acetate on estrogen-stimulated growth of dimethylbenza-anthracene-induced mammary carcinoma in rats. Int J Cancer 1997;73:580–86
   PubMed Web of Science ®Google Scholar
• Martel C, Sourla A, Pelletier G et al. Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in rats. J Endocr 1998;157:433–42
   PubMed Web of Science ®Google Scholar